Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pluristem Therapeutics Inc. (PSTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6400-0.0800 (-2.94%)
At close: 4:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

    Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on muscle regeneration following hip fracture surgery on November 22 at 9:15am EST HAIFA, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnologycompany announced today that its multinational Phase IIImulticenter, randomized, d

  • GlobeNewswire

    Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

    Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and working with other industry and academic leaders in genome editingHAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an additional grant from the Israel Innovation Authority (IIA)

  • GlobeNewswire

    Pluristem CEO Issues Shareholder Update

    Figure 1 Clinical Pipeline: Milestones HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Dear Shareholders, Less than three months into a new fiscal year, there are several important developments on the horizon for Pluristem, including four studies heading to clinical readout in the coming quarters. These s

Advertisement
Advertisement